Information Links
Mims
Main Navigation
Drugs
Conditions
News and resources
MIMS HostedGuidelines - Cancer
Quick-reference summaries of key national treatment guidance for malignant conditions including haematological cancers and solid tumours.
MIMS summaries
At-a-glance summaries of authoritative evidence-based clinical guidelines for malignant conditions commonly encountered in primary care, prepared by the MIMS editorial team.
Initiating Treatment with Transdermal Opioids
Guidance on dosing for fentanyl and buprenorphine patches.
Syringe Driver Drug Compatibility
Compatibility of drugs mixed in a syringe driver.
Co-Analgesics for Use in Cancer Pain
Agents and doses for different types of cancer pain.
WHO Pain Ladder for Cancer Pain Relief in Adults
Summary of 3-step approach to analgesia in cancer patients.
Opioid Analgesics: Approximate Potency Equivalence with Oral Morphine
Guide to potencies of opioid analgesics, for dose conversion.
Prescribing of Strong Opioids for Pain in Palliative Care of Adults (NICE Guideline)
Summary of NICE guidance on prescribing opioid analgesics.
NICE technology appraisals
Decisions by the National Institute for Health and Care Excellence on NHS access to treatments for malignant conditions.
-
Brentuximab Vedotin for Treating CD30-Positive Hodgkin Lymphoma (TA446)
-
Pembrolizumab for Untreated PD-L1-Positive Metastatic Non-Small-Cell Lung Cancer (TA447)
-
Everolimus and Sunitinib for Treating Unresectable or Metastatic Neuroendocrine Tumours in People with Progressive Disease (TA449)
-
Blinatumomab for Previously Treated Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukaemia (TA450)
-
Ponatinib for Treating Chronic Myeloid Leukaemia and Acute Lymphoblastic Leukaemia (TA451)
-
Afatinib for Treating Advanced Squamous Non-Small-Cell Lung Cancer after Platinum-based Chemotherapy (Terminated Appraisal) (TA444)
-
Pegylated Liposomal Irinotecan for Treating Pancreatic Cancer after Gemcitabine (TA440)
-
Panitumumab in Combination with Chemotherapy for the Treatment of Metastatic Colorectal Cancer (terminated appraisal) (TA240)
-
Alectinib for Previously Treated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer (terminated appraisal) (TA438)
-
Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer (TA439)
-
Bevacizumab for Treating EGFR Mutation-Positive Non-Small-Cell Lung Cancer (terminated appraisal) (TA436)
-
Elotuzumab for Previously Treated Multiple Myeloma (terminated appraisal) (TA434)
-
Everolimus for Advanced Renal Cell Carcinoma after Previous Treatment (TA432)
-
Ibrutinib for Previously Treated Chronic Lymphocytic Leukaemia and Untreated Chronic Lymphocytic Leukaemia with 17p Deletion or TP53 Mutation (TA429)
-
Pomalidomide for Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib (TA427)
-
Pembrolizumab for Treating PD-L1-Positive Non-Small-Cell Lung Cancer After Chemotherapy (TA428)
-
Dasatinib, Nilotinib and Imatinib for Untreated Chronic Myeloid Leukaemia (TA426)
-
Dasatinib, Nilotinib and High-Dose Imatinib for Treating Imatinib-Resistant or Intolerant Chronic Myeloid Leukaemia (TA425)
-
Pertuzumab for the Neoadjuvant Treatment of HER2-Positive Breast Cancer (TA424)
-
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After 2 or More Chemotherapy Regimens (TA423)
-
Crizotinib for Previously Treated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer (TA422)
-
Everolimus with Exemestane for Treating Advanced Breast Cancer after Endocrine Therapy (TA421)
-
Nivolumab for Previously Treated Advanced Renal Cell Carcinoma (TA417)
-
Osimertinib for Treating Locally Advanced or Metastatic EGFR T790M Mutation-Positive Non-Small-Cell Lung Cancer (TA416)
-
Cobimetinib in Combination with Vemurafenib for Treating Unresectable or Metastatic BRAF V600 Mutation-Positive Melanoma (TA414)
-
Necitumumab for Untreated Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (TA411)
-
Talimogene Laherparepvec for Treating Unresectable Metastatic Melanoma (TA410)
-
Pegaspargase for Treating Acute Lymphoblastic Leukaemia (TA408)
-
Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer (TA406)
-
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer (TA405)
-
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer (TA404)
-
Pemetrexed Maintenance Treatment for Non-Squamous Non-Small-Cell Lung Cancer after Pemetrexed and Cisplatin (TA402)
-
Ramucirumab for Previously Treated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (TA403)
-
Bosutinib for Previously Treated Chronic Myeloid Leukaemia (TA401)
-
Abiraterone for Treating Metastatic Hormone-Relapsed Prostate Cancer before Chemotherapy is Indicated (TA387)
-
Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30% Bone Marrow Blasts (TA399)
-
Nivolumab in Combination with Ipilimumab for Treating Advanced Melanoma (TA400)
-
Trametinib in Combination with Dabrafenib for Treating Unresectable or Metastatic Melanoma (TA396)
-
Ceritinib for Previously Treated Anaplastic Lymphoma Kinase Positive Non-Small-Cell Lung Cancer (TA395)
-
Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Treated with Docetaxel (TA391)
-
Carmustine Implants and Temozolomide for the Treatment of Newly Diagnosed High-Grade Glioma (TA121)
-
Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel, Trabectedin and Gemcitabine for Treating Recurrent Ovarian Cancer (TA389)
-
Abiraterone for Treating Metastatic Hormone-Relapsed Prostate Cancer before Chemotherapy is Indicated (TA387)
-
Cancer, Brain (Recurrent Malignant Glioma): Temozolomide (NICE)
-
Ruxolitinib for Treating Disease-Related Splenomegaly or Symptoms in Adults with Myelofibrosis (TA386)
-
Nivolumab for Treating Advanced (Unresectable or Metastatic) Melanoma (TA384)
-
Olaparib for Maintenance Treatment of Relapsed, Platinum-Sensitive, BRCA Mutation-Positive Ovarian, Fallopian Tube and Peritoneal Cancer after Response to Second-Line or Subsequent Platinum-Based Chemotherapy (TA381)
-
Panobinostat for Treating Multiple Myeloma After at Least 2 Previous Treatments (TA380)
-
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy (TA378)
-
Enzalutamide for Treating Metastatic Hormone-Relapsed Prostate Cancer before Chemotherapy is Indicated (TA377)
-
Radium-223 Dichloride for Treating Hormone-Relapsed Prostate Cancer with Bone Metastases (TA376)
-
Erlotinib and Gefitinib for Treating Non-Small-Cell Lung Cancer That Has Progressed After Prior Chemotherapy (TA374)
-
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane (TA371)
-
Bortezomib for Previously Untreated Mantle Cell Lymphoma (TA370)
-
Pembrolizumab for Advanced Melanoma not Previously Treated with Ipilimumab (TA366)
-
Paclitaxel as Albumin-Bound Nanoparticles in Combination with Gemcitabine for Previously Untreated Metastatic Pancreatic Cancer (TA360)
-
Idelalisib for Treating Chronic Lymphocytic Leukaemia (TA359)
-
Pembrolizumab for Treating Advanced Melanoma After Disease Progression with Ipilimumab (TA357)
-
Nintedanib for Previously Treated Locally Advanced, Metastatic, or Locally Recurrent Non-Small-Cell Lung Cancer (TA347)
-
Obinutuzumab in Combination with Chlorambucil for Untreated Chronic Lymphocytic Leukaemia (TA343)
-
Ofatumumab in Combination with Chlorambucil or Bendamustine for Untreated Chronic Lymphocytic Leukaemia (TA344)
-
Pomalidomide for Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib (TA338)
-
Imatinib for the Adjuvant Treatment of Gastrointestinal Stromal Tumours (TA326) (review of TA196)
-
Dabrafenib for Treating Unresectable or Metastatic BRAF V600 Mutation‑Positive Melanoma (TA321)
-
Lenalidomide for Treating Myelodysplastic Syndromes Associated with an Isolated Deletion 5q Cytogenetic Abnormality (TA322)
-
Enzalutamide for Metastatic Hormone-Relapsed Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen (TA316)
-
Ipilimumab for Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (TA319)
-
Bortezomib for Induction Therapy in Multiple Myeloma Before High-Dose Chemotherapy and Autologous Stem Cell Transplantation (TA311)
-
Afatinib for Treating Epidermal Growth Factor Receptor Mutation-Positive Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (TA310)
-
Pemetrexed Maintenance Treatment Following Induction Therapy with Pemetrexed and Cisplatin for Non-Squamous Non-Small-Cell Lung Cancer (TA309)
-
Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy for Treating Metastatic Colorectal Cancer that has Progressed Following Prior Oxaliplatin-Based Chemotherapy (TA307)
-
Pixantrone Monotherapy for Treating Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-cell Lymphoma (TA306)
-
Bosutinib for Previously Treated Chronic Myeloid Leukaemia (TA299)
-
Crizotinib for Previously Treated Non-Small-Cell Lung Cancer Associated with an Anaplastic Lymphoma Kinase Fusion Gene (TA296)
-
Everolimus in Combination with Exemestane for Treating Advanced HER2-Negative Hormone-Receptor-Positive Breast Cancer after Endocrine Therapy (TA295)
-
Ruxolitinib for Disease-Related Splenomegaly or Symptoms in Adults with Myelofibrosis (TA289)
-
Bevacizumab in Combination With Gemcitabine and Carboplatin for Treating the First Recurrence of Platinum-Sensitive Advanced Ovarian Cancer (TA285)
-
Bevacizumab in Combination with Paclitaxel and Carboplatin for First-Line Treatment of Advanced Ovarian Cancer (TA284)
-
Denosumab for the Treatment of Therapy-Induced Bone Loss in Non-Metastatic Prostate Cancer (terminated appraisal) (TA194)
-
Vinflunine for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract (TA272)
MIMS Clinics
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
